Shares of Contineum Therapeutics, Inc. (CTNM) have gained 14% over the past four weeks to close the last trading session at $14.63, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21.83 indicates a potential upside of 49.2%.The mean estimate comprises six short-term price targets with a standard deviation of $4.92. While the lowest estimate of $14.00 indicates a 4.3% decline fr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f ...

Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES SAN DIEGO – May 5, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2026 financial results and affirmed its key clinical development milestones. Forward-Looking ...

Corporate Presentation May 2026 Disclaimer This presentation by Contineum Therapeutics, Inc. ("Contineum", "We" or "Our) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955. All statements other than statements of historical facts contained in this presentation, including without limitation statements regarding our future results of operations and financial position, future revenue, timing, progress and expected results of our clinical trials and ou ...